Sanofi India (BSE:500674) - Aandelenkoers, Nieuws & Analyse

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

500674 Overzicht aandelen

Sanofi India Limited produceert en verhandelt geneesmiddelen en farmaceutische producten in India, Singapore en internationaal.

Over het bedrijf

500674 fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	0/6
Prestaties in het verleden	2/6
Financiële gezondheid	6/6
Dividenden	4/6

Beloningen

De koers-winstverhouding ( 30.8 x) ligt onder de Indian markt ( 34.3 x)

Risicoanalyse

Hoog niveau van niet-contante inkomsten

De winst zal naar verwachting de komende drie jaar met gemiddeld 8.5% per jaar dalen.

Dividend van 2.36% wordt niet goed gedekt door vrije kasstromen

Sanofi India Limited Concurrenten

Jubilant Pharmova

BSE:530019

₹176.9b

Concord Biotech

NSEI:CONCORDBIO

₹201.2b

Glenmark Life Sciences

NSEI:GLS

₹138.1b

Laurus Labs

NSEI:LAURUSLABS

₹248.4b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Sanofi India
Historische aandelenkoersen
Huidige aandelenkoers	₹6,887.30
52 Week Hoogtepunt	₹10,526.05
52 Week Laag	₹5,850.55
Bèta	0.30
11 maand verandering	-5.19%
3 maanden verandering	4.63%
1 Jaar Verandering	-6.05%
33 jaar verandering	-14.07%
5 jaar verandering	17.41%
Verandering sinds IPO	1,867.80%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	500674	IN Pharmaceuticals	IN Markt
7D	1.8%	-0.4%	-2.6%
1Y	-6.1%	60.6%	42.2%

Rendement versus industrie: 500674 presteerde slechter dan de Indian Pharmaceuticals -sector, die het afgelopen jaar een rendement van 58.2 % opleverde.

Rendement versus markt: 500674 presteerde slechter dan Indian Market, dat het afgelopen jaar een rendement van 44.2 % opleverde.

Prijsvolatiliteit

Is 500674's price volatile compared to industry and market?
500674 volatility
500674 Average Weekly Movement	3.2%
Pharmaceuticals Industry Average Movement	6.1%
Market Average Movement	6.2%
10% most volatile stocks in IN Market	9.3%
10% least volatile stocks in IN Market	3.9%

Stabiele aandelenkoers: 500674 heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 3% ) van 500674 is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1956	2,174	Rodolfo Hrosz	www.sanofiindialtd.com

Sanofi India Limited produceert en verhandelt geneesmiddelen en farmaceutische producten in India, Singapore en internationaal. Het bedrijf levert farmaceutische producten in verschillende therapeutische gebieden, zoals diabetes, cardiologie, trombose, infecties, centraal zenuwstelsel, anti-infectiva, epilepsie, allergie en vitamines, mineralen en supplementen, evenals pijnverzorging en voedingsgezondheid onder de merknamen Lantus, Toujeo, Clexane, Amaryl, Cardace, Glimepiride, Cetapin, Targocid, Frisium, Combiflam, DePura, Allegra en Avil via onafhankelijke distributeurs. Het exporteert zijn producten ook naar ongeveer 35 landen.

Sanofi India Limited Samenvatting

Hoe verhouden de winst en inkomsten van Sanofi India zich tot de beurswaarde?
500674 fundamentele statistieken
Marktkapitalisatie	₹158.93b
Inkomsten(TTM)	₹5.29b
Inkomsten(TTM)	₹27.89b

30.0x

Koers/Winstverhouding

5.7x

P/S-verhouding

Is 500674 overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
500674 resultatenrekening (TTM)
Inkomsten	₹27.89b
Kosten van inkomsten	₹11.93b
Brutowinst	₹15.96b
Overige uitgaven	₹10.67b
Inkomsten	₹5.29b

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	229.61
Brutomarge	57.23%
Nettowinstmarge	18.96%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde 500674 op de lange termijn?

Bekijk historische prestaties en vergelijking

Dividenden

2.4%

Huidig dividendrendement

70%

Uitbetalingsratio

500674 Overzicht aandelen

Beloningen

Risicoanalyse

Sanofi India Limited Concurrenten

BSE:530019

₹176.9b

NSEI:CONCORDBIO

₹201.2b

NSEI:GLS

₹138.1b

NSEI:LAURUSLABS

₹248.4b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Sanofi India Limited Announces Resignation of Radhika Shah as Head of Legal and Company Secretary

Sanofi India Limited Announces Cessation of Cyrus Aibara as Senior Director Diabetes

Price target decreased by 9.1% to ₹8,501

New major risk - Revenue and earnings growth

Second quarter 2024 earnings released: EPS: ₹29.61 (vs ₹53.37 in 2Q 2023)

Sanofi India Limited Announces Resignation of Nitin Joshi, Head - Supply Chain, Effective 31 July 2024

Recent updates

Sanofi India Limited Announces Resignation of Radhika Shah as Head of Legal and Company Secretary

Sanofi India Limited Announces Cessation of Cyrus Aibara as Senior Director Diabetes

Price target decreased by 9.1% to ₹8,501

New major risk - Revenue and earnings growth

Second quarter 2024 earnings released: EPS: ₹29.61 (vs ₹53.37 in 2Q 2023)

Sanofi India Limited Announces Resignation of Nitin Joshi, Head - Supply Chain, Effective 31 July 2024

Sanofi India Limited to Report Q2, 2024 Results on Jul 26, 2024

Sanofi India Limited Announces Resignation of Shalini Menon, General Medicines Medical Head and India Medical Lead, Effective July 5, 2024

Less than half of directors are independent

Sanofi India Limited Appoints N. Suresh Babu as Sales & Customer Engagement Head Diabetes, Effective July 1, 2024

New major risk - Share price stability

Investor sentiment improves as stock rises 17%

Sanofi India Limited Announces Resignation of Shalini Menon as General Medicines Medical Head and India Medical Lead

First quarter 2024 earnings released: EPS: ₹59.31 (vs ₹82.67 in 1Q 2023)

Sanofi India Limited Announces Appointment of Flovie Martins as Head of Corporate Communications and Corporate Social Responsibility

Sanofi India Limited Announces Resignation of Marc-Antoine Lucchini as Non-Executive Director from the Board of Directors, Member of the Nomination and Remuneration Committee

Sanofi India Limited Announces Resignation of Marc-Antoine Lucchini as Non-Executive Director, Member of the Nomination and Remuneration Committee

Final dividend of ₹117 announced

Upcoming dividend of ₹50.00 per share

Price target increased by 8.8% to ₹9,371

Full year 2023 earnings released: EPS: ₹262 (vs ₹269 in FY 2022)

Sanofi India Limited, Annual General Meeting, May 14, 2024

Sanofi India Limited Recommends Final Dividend for the Financial Year Ended 31St December 2023, Payable on or After 24 May 2024

Sanofi India Limited to Report Q4, 2023 Results on Feb 23, 2024

Sanofi India Limited Appoints Radhika Shah as Head of Legal, Effective 15 January 2024

Price target increased by 12% to ₹8,392

Third quarter 2023 earnings released: EPS: ₹65.95 (vs ₹56.84 in 3Q 2022)

Sanofi India Limited Announces the Resignation of Vaibhav Karandikar as Whole-Time Director

Sanofi India Limited to Report Q3, 2023 Results on Nov 08, 2023

Sanofi India Limited Appoints Surabhi Kaul as India People Director and Will Be Part of the Senior Management Personnel

Less than half of directors are independent

Sanofi India Limited Announces Executive Changes

Sanofi India Limited Announces Resignation of Vinita Korti Patil as Senior Legal Director - South Asia, Effective 7 December 2023

Second quarter 2023 earnings released: EPS: ₹53.37 (vs ₹52.28 in 2Q 2022)

Sanofi India Limited Announces Resignation of Gaurav Bahadur as People Director

Less than half of directors are independent

Sanofi India Limited to Report Q2, 2023 Results on Aug 10, 2023

Sanofi India Limited Announces Resignation of Annapurna Das as Non-Executive Director and Member of the Audit Committee, Effective 31 July 2023

Upcoming dividend of ₹377 per share at 3.3% yield

Price target decreased by 7.9% to ₹6,604

Price target decreased by 8.5% to ₹6,986

Sanofi India Limited to Report Q4, 2022 Results on Feb 23, 2023

High number of new directors

Third quarter 2022 earnings released: EPS: ₹56.84 (vs ₹230 in 3Q 2021)

Sanofi India Limited Announces Change in Directorate

Sanofi India Limited to Report Q3, 2022 Results on Nov 03, 2022

Upcoming dividend of ₹193 per share

Price target decreased to ₹7,800

Second quarter 2022 earnings released: EPS: ₹52.28 (vs ₹77.42 in 2Q 2021)

Sanofi India Limited Approves One-Time Special Interim Dividend, Payable on August 22, 2022

Sanofi India Limited to Report Q2, 2022 Results on Jul 26, 2022

First quarter 2022 earnings released: EPS: ₹104 (vs ₹63.35 in 1Q 2021)

Less than half of directors are independent

Sanofi India Appoints Rodolfo Hrosz as Managing Director

Sanofi India Limited to Report Q1, 2022 Results on Apr 26, 2022

Upcoming dividend of ₹490 per share

Full year 2021 earnings released: EPS: ₹410 (vs ₹207 in FY 2020)

Sanofi India Limited Proposes Final Dividend for the Financial Year Ended December 31, 2021, Payable on or After May 4, 2022

Sanofi India Limited, Annual General Meeting, Apr 26, 2022